Nucleic Acid Sample Preparation Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product (Consumables, Systems, Accessories & Components), By Technology (Spin-Column Based Technology, Magnetic-Bead Based Technology, Others), By Therapeutic Area (Oncology, Infectious Disease, Human Genetics/Population Genetics, Others), By Application (Genomics, Proteomics, Others), By End Users (Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Clinical and Diagnostic Laboratories, Other), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.99 Billion
CAGR (2026-2031)	6.69%
Fastest Growing Segment	Genomics
Largest Market	North America
Market Size (2031)	USD 4.41 Billion

Market Overview

The Global Nucleic Acid Sample Preparation Market will grow from USD 2.99 Billion in 2025 to USD 4.41 Billion by 2031 at a 6.69% CAGR. Nucleic acid sample preparation involves the extraction, isolation, and purification of DNA and RNA from biological matrices to produce high-quality substrates for downstream analytical applications such as amplification and sequencing. The market is primarily supported by the escalating prevalence of infectious diseases and cancer, which necessitates robust molecular diagnostic testing for effective patient management. Furthermore, the burgeoning field of precision medicine drives the demand for reliable extraction methods that can yield high-purity nucleic acids from complex biological samples to ensure data integrity in genomic profiling.

According to the Pharmaceutical Research and Manufacturers of America, in 2024, there were more than 8,000 medicines in clinical development, underscoring the substantial demand for sample processing workflows within the biopharmaceutical research sector. Despite these strong growth contributors, the Global Nucleic Acid Sample Preparation Market faces a significant challenge regarding the high capital cost associated with automated extraction platforms, which can impede adoption in smaller laboratories and resource-limited diagnostic settings.

Key Market Drivers

The rising incidence of infectious diseases and genetic disorders constitutes a primary driver for the nucleic acid sample preparation market. As the prevalence of pathologies such as cancer escalates, clinical laboratories require efficient extraction protocols to isolate genetic material for accurate diagnosis and monitoring. This disease burden necessitates high-volume processing of biological specimens, directly increasing the consumption of sample preparation kits and reagents. According to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025' report, it was projected that more than 2 million new cancer cases would be diagnosed in the United States in 2025, highlighting the critical need for molecular profiling in oncology. Consequently, laboratories are increasingly reliant on consistent workflows to ensure purified DNA and RNA are available for critical diagnostic assays.

Surging demand for Next-Generation Sequencing (NGS) and molecular diagnostics further amplifies market expansion by imposing stringent quality standards on extracted nucleic acids. Modern genomic applications require high-purity inputs to generate reliable data for precision medicine and liquid biopsy applications, thereby driving the adoption of automated extraction technologies. According to Illumina, Inc., October 2025, in the 'Financial Results for Third Quarter of Fiscal Year 2025' report, the company recorded $1.08 billion in revenue, attributing performance to acceleration in the clinical genomics segment. This uptake in clinical sequencing underscores the dependency of molecular diagnostic platforms on upstream sample processing. Reflecting this broader industry momentum, according to QIAGEN, in 2025, the company reported second-quarter net sales of $534 million, driven significantly by demand for sample technologies and diagnostic solutions.

Download Free Sample Report

Key Market Challenges

The high capital investment required for automated nucleic acid extraction platforms constitutes a formidable barrier to market expansion, particularly for smaller diagnostic centers and academic research facilities. While these automated systems offer superior throughput and consistency, the substantial initial expenditure often exceeds the budgetary limits of laboratories in resource-constrained settings. Consequently, many institutions are forced to continue relying on labor-intensive manual extraction methods. This reluctance or inability to upgrade to automated workflows directly restricts the total addressable market for manufacturers, as the adoption of advanced sample preparation technologies remains concentrated primarily within large-scale reference laboratories with significant funding.

The impact of these budgetary constraints on market growth is evidenced by recent procurement trends in the healthcare sector. According to the American Hospital Association, in 2025, a survey revealed that 94% of health care administrators anticipated delaying equipment upgrades to manage persistent financial strain. This widespread deferral of capital projects directly hampers the nucleic acid sample preparation market, as laboratories are compelled to extend the lifecycle of legacy equipment rather than investing in the modern, automated workflows necessary for scaling genomic profiling and diagnostic testing.

Key Market Trends

The increasing adoption of automated liquid handling workstations is fundamentally reshaping laboratory workflows by addressing the critical need for reproducibility and operational efficiency. Unlike manual techniques, which are prone to user-to-user variability, automated systems ensure standardized nucleic acid yields essential for large-scale biobanking and pharmaceutical validation studies. This transition is further accelerated by the industry's push to minimize technicians' hands-on time, allowing staff to focus on data analysis rather than repetitive pipetting tasks. The financial impact of this operational shift is evident in the performance of key infrastructure providers. According to Agilent Technologies, February 2025, in the 'Agilent Reports First-Quarter Fiscal Year 2025 Financial Results' report, the company announced Life Sciences and Diagnostics Markets Group revenue of $647 million, reflecting sustained investment in automated laboratory instrumentation and workflow solutions.

Concurrently, the development of high-precision kits for single-cell genomics has emerged as a vital trend, driven by the requirement to isolate genetic material from individual cells with minimal loss. Traditional bulk extraction methods often mask cellular heterogeneity, creating a gap that specialized microfluidic and bead-based protocols now fill for applications in immunology and developmental biology. These specialized kits are engineered to handle minute input volumes while preserving RNA integrity, a capability that has become indispensable for spatial biology and complex tissue profiling. This segment's commercial significance is highlighted by recent industry performance. According to 10x Genomics, November 2025, in the '10x Genomics Reports Third Quarter 2025 Financial Results' report, the company recorded revenue of $149 million, underscoring the strong market appetite for tools enabling high-resolution single-cell and spatial analysis.

Segmental Insights

The Genomics segment represents the fastest-growing category within the Global Nucleic Acid Sample Preparation Market, driven by the escalating demand for precision medicine and advanced genetic diagnostics. This rapid expansion is largely attributed to the increasing prevalence of chronic and infectious diseases, which necessitates high-quality DNA and RNA isolation for downstream analysis. Furthermore, substantial research investments facilitate the adoption of Next-Generation Sequencing, requiring reliable sample extraction to ensure assay accuracy. Consequently, the critical role of nucleic acid purification in disease profiling and therapeutic development continues to sustain this segment's accelerated market performance.

Regional Insights

North America commands a leading share of the Global Nucleic Acid Sample Preparation Market, underpinned by a mature biotechnology sector and substantial R&D expenditure. The region’s dominance is reinforced by the presence of major industry innovators and significant funding initiatives for genomic research from bodies such as the National Institutes of Health (NIH). Additionally, supportive regulatory frameworks established by the U.S. Food and Drug Administration (FDA) facilitate the rapid commercialization of precision diagnostics and personalized medicine solutions. These factors, combined with the early adoption of automated genomic technologies, sustain North America’s competitive advantage in the global landscape.

Recent Developments

• In July 2024, Promega launched the Maxwell DE System, an automated differential extraction solution specifically developed to address backlogs in forensic laboratories processing sexual assault kits. This new system eliminates the need for manual DNA purification following cell separation, allowing for direct quantification and analysis of sperm and non-sperm fractions. By automating the most labor-intensive steps of the workflow, the platform significantly reduces hands-on time and the potential for human error. The system is designed to process multiple samples simultaneously, enabling forensic analysts to increase their throughput and deliver consistent, reliable results for critical casework.
• In May 2024, Qiagen launched the QIAseq Multimodal DNA/RNA Library Kit, a new product designed to facilitate multiomic studies by enabling the simultaneous preparation of DNA and RNA libraries from a single sample. This innovative kit streamlines the workflow for next-generation sequencing applications, such as whole genome and whole transcriptome sequencing, as well as downstream target enrichment. The solution allows researchers to consolidate multiple workflows into one, significantly saving laboratory time and resources while preserving valuable sample material. It is compatible with various sequencing platforms, making it a versatile tool for precision medicine and translational research.
• In March 2024, Revvity introduced a comprehensive, end-to-end workflow solution designed to advance newborn sequencing research. This flexible offering includes Chemagic kits and instruments for automated nucleic acid extraction, along with liquid handling workstations for precise library preparation. The workflow also integrates dried blood spot collection devices and advanced software capabilities to streamline the identification of variants in over 350 genes. By consolidating these critical sample preparation and analysis steps into a single solution, the company aims to accelerate the democratization of genomic sequencing and support laboratories in diagnosing rare diseases more efficiently.
• In February 2024, Integrated DNA Technologies announced a strategic collaboration with Element Biosciences to accelerate next-generation sequencing workflows for the AVITI System. As part of this partnership, the company launched a suite of xGen products specifically optimized for this platform, including adapters, primers, and universal blocking oligos. These new solutions enable users to perform native library construction and hybridization capture enrichment directly on the system, supporting applications such as DNA, RNA, and methylation sequencing. The collaboration aims to provide researchers with improved tools for genomic discovery by minimizing sequence errors and streamlining the preparation process.

Key Market Players

• BGI Group
• F. Hoffmann-La Roche Ltd
• Danaher Corporation
• Eppendorf SE
• BIONEER CORPORATION
• Endress+Hauser Group Services AG
• Merck KGaA
• Norgen Biotek Corp.
• Aurora Biomed Inc.
• Agilent Technologies, Inc.

By Product	By Technology	By Therapeutic Area	By Application	By End Users	By Region
Consumables Systems Accessories & Components	Spin-Column Based Technology Magnetic-Bead Based Technology Others	Oncology Infectious Disease Human Genetics/Population Genetics Others	Genomics Proteomics Others	Academic and Research Institutions Pharmaceutical and Biotechnology Companies Clinical and Diagnostic Laboratories Other	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Nucleic Acid Sample Preparation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Nucleic Acid Sample Preparation Market, By Product:

• Consumables
• Systems
• Accessories & Components

• Nucleic Acid Sample Preparation Market, By Technology:

• Spin-Column Based Technology
• Magnetic-Bead Based Technology
• Others

• Nucleic Acid Sample Preparation Market, By Therapeutic Area:

• Oncology
• Infectious Disease
• Human Genetics/Population Genetics
• Others

• Nucleic Acid Sample Preparation Market, By Application:

• Genomics
• Proteomics
• Others

• Nucleic Acid Sample Preparation Market, By End Users:

• Academic and Research Institutions
• Pharmaceutical and Biotechnology Companies
• Clinical and Diagnostic Laboratories
• Other

• Nucleic Acid Sample Preparation Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE